Structure-Guided Discovery of Novel N 4 -(Substituted Thiazol-2-yl)- N 2 -(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Bei Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, P. R. Chi…. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 2, Cyclin-Dependent Kinase 9, Biological Availability, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Guangzhou Municipal Science and Technology Project, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
CDK2 and CDK9 play pivotal roles in cell cycle progression and gene transcription, respectively, making them promising targets for cancer treatment. Herein, we discovered a series of N4-(substituted thiazol-2-yl)-N2-(4-substituted phenyl)pyrimidine-2,4-diamines as highly potent CDK2/9 dual inhibitors. Especially, compound 20a significantly inhibited CDK2 (IC50 = 0.004 μM) and CDK9 (IC50 = 0.009 μM), achieving a 1000- and 2800-fold improvement over lead compound 11, and demonstrating broad antitumor efficacy. Mechanistic studies indicated that 20a effectively and simultaneously suppressed CDK2 and CDK9 proteins in the HCT116 cell line, leading to G2/M cell cycle arrest and cell apoptosis by regulating cell cycle- and apoptosis-related protein expression. Most importantly, 20a exhibited 86.7% oral bioavailability in rats and effectively inhibited tumor growth in HCT116 xenograft and C6 glioma rat models without significant toxicity. Overall, these observations clearly confirmed the promising therapeutic strategy of CDK2/9 dual inhibitors and provided a novel potent candidate for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, P. R. China.
ORCID-Profile: Peiliang Zhao
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Project
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Zhang, B., Li, Y., Lin, Y., Wang, T., Chen, L., Cai, J., Ji, T., Diao, P., Ma, Y., Zhang, Y., You, W., Chen, J., & Zhao, P. (2025). Structure-Guided Discovery of Novel N 4 -(Substituted Thiazol-2-yl)- N 2 -(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02441
Vancouver
Zhang B, Li Y, Lin Y, Wang T, Chen L, Cai J, et al. Structure-Guided Discovery of Novel N 4 -(Substituted Thiazol-2-yl)- N 2 -(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02441
BibTeX
@article{Zhang2025,
author = {Zhang, Bei and Li, Yanhong and Lin, Yukang and Wang, Ting and Chen, Lin and Cai, Jianfan and Ji, Tangyang and Diao, Pengcheng and Ma, Yufeng and Zhang, Yanting and You, Wenwei and Chen, Jingkao and Zhao, Peiliang},
title = {Structure-Guided Discovery of Novel N 4 -(Substituted Thiazol-2-yl)- N 2 -(4-Substituted phenyl)pyrimidine-2,4-Diamines as Potent CDK2 and CDK9 Dual Inhibitors with High Oral Bioavailability},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02441}
}
EUVIMED